ArticleMolecular biology reports2025
Rosmarinic acid: a promising agent for male rats' renal protection against ischemia/reperfusion injury.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comprehensive Profiling of Chemical Constituents in Niaoduqing Granules by Ultra-High-Performance Liquid Chromatography-Q-Exactive Orbitrap Mass Spectrometry and Identification of Potential Renoprotective Active Components.Journal of separation science · 2026Article
- Plant metabolites: potential treatments for ischemic acute kidney injury.Frontiers in pharmacology · 2026Review
- Dihydroquercetin/Taxifolin Inhibits METTL3/mKidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThis study investigated the potential anti-inflammatory and antioxidant renoprotective effects of rosmarinic acid, a naturally occurring phenylpropanoid, against renal damage and dysfunction following renal ischemia/reperfusion (I/R) in male rats.
methodsThe rats were divided into four separate groups (n = 7 per group): sham (1 ml 1% DMSO, i.p.), sham + RA (rosmarinic acid, 100 mg/kg in 1 ml 1% DMSO, i.p.), I/R (bilateral renal ischemia for 45 min followed by 24 h reperfusion), I/R + RA (rosmarinic acid, 100 mg/kg in 1 ml 1% DMSO, i.p. once, 30 min prior to ischemia). After the 24-hour reperfusion period, kidney tissue samples, blood, and 24-hour urine were taken.
resultsIn contrast to the sham and sham + RA groups, IR injury (IRI) resulted in renal dysfunction (increased fractional excretion of sodium and decreased creatinine clearance), raised malondialdehyde levels, enhanced TLR4 (Toll-like receptor 4), NFĸB (nuclear factor-ĸB) and TNF-α (tumor necrosis factor-alpha) gene expression levels, and histological lesions in kidney tissue Administration of rosmarinic acid attenuated each change.
conclusionsRosmarinic acid protects the kidney against IRI by reducing inflammation and oxidative stress. Rosmarinic acid's anti-inflammatory and antioxidant properties most likely play an important role in addressing functional problems and protecting the kidney from IRI.
Indexed as
Identifiers
40106003What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.